# A 2-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥ 2 Years Old and Young Adults With Dravet Syndrome

> **NCT02926898** · PHASE3 · COMPLETED · sponsor: **Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.** · enrollment: 87 (actual)

## Conditions studied

- Dravet Syndrome

## Interventions

- **DRUG:** ZX008 (Fenfluramine Hydrochloride)
- **DRUG:** Matching Placebo

## Key facts

- **NCT ID:** NCT02926898
- **Lead sponsor:** Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-27
- **Primary completion:** 2018-06-05
- **Final completion:** 2018-06-05
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2022-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02926898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02926898, "A 2-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥ 2 Years Old and Young Adults With Dravet Syndrome". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02926898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*